| Description : |
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization. |
| Source : |
HEK293 |
| Species : |
Human |
| Tag : |
His |
| Predicted N Terminal : |
Phe 31 (ITGAV) & Glu 43 (ITGB8) |
| Form : |
Lyophilized from 0.22 μm filtered solution in Tris, NaCl and MgCl2, 10% trehalose. |
| Bio-activity : |
Measured by its binding ability in a functional ELISA. Immobilized Human ITGAVB8, His Tag at 5μg/mL (100 μL/well) can bind biotinylated Human TGF-Beta 1 / TGFB1, His Tag & Avi Tag with a linear range of 1-25 ng/mL. |
| Molecular Mass : |
Human ITGAV & ITGB8 Heterodimer Protein, produced by co-expression of ITGAV and ITGB8, has a calculated MW of 113 kDa (ITGAV) and 75.5 kDa (ITGB8). Subunit ITGAV is fused with polyhistidine tag at the C-terminus and followed by a acidic tail and subunit ITGB8 contains no tag but a basic tail at the C-terminus. The reducing (R) protein migrates as 145 kDa (ITGAV) and 100-116 kDa (ITGB8) respectively due to glycosylation. |
| Protein length : |
Phe 31 - Val 992 (ITGAV) & Glu 43 - Arg 684 (ITGB8) |
| Endotoxin : |
Less than 1.0 EU per μg by the LAL method. |
| Purity : |
>95% as determined by SDS-PAGE. |
| Storage : |
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. |
| Storage buffer : |
Tris, NaCl and MgCl2 |
| Reconstitution : |
It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
| Shipping : |
Powder,RT |
